B Cell Maturation Antigen (BCMA) Targeted Therapy Markets, 2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026” report has been added to ResearchAndMarkets.com’s offering.

The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing.

Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company.

Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.

Over a period of time, the cancer research has deviated for conventional approach and is directed towards the development of novel drugs that selectively targets the oncogenes, thereby reducing the adverse side effects. Genomic analysis have shown that B-cell maturation antigen or CD269 is restrictively expressed in both normal as well as malignant cells at high levels, thus making it an ideal target antigen for development of novel multiple myeloma therapies.

BCMA is a member of tumor necrosis factor family and has critical role in the regulating B-cell proliferation and survival. The interaction of BCMA with its ligand has also shown to promote the progression of cancer. Further, studies have also demonstrated that BCMA is central to the survival of multiple myeloma cells. Therefore, researchers have adopted several approaches to target this antigen as an alternative for the management of multiple myeloma.

Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market.

Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.

In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication.

The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market.

In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.

The active research and development in this sector will drive the growth of the market. At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period.

For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:

• Research Methodology
• Global & Regional Market Analysis
• Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion
• Market and Drug Sales Insight 2020 Till 2026
• Approved Drug In Market: 2 Drugs
• Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026
• Future Market Assessment By Indication Till 2026
• Ongoing Clinical Trials Assessment by Status, Phase & Region
• Key Market Dynamics
• Competitor Landscape

Key Topics Covered:

1. Introduction to BCMA Targeting Therapy

1.1 Overview

1.2 History of BCMA Targeting Therapeutics

2. BCMA Targeting Therapeutics Mechanism of Action

3. BCMA As Ideal Target for Hematological Cancer

4. Global BCMA Targeting Drugs Market Analysis

4.1 Overview

4.2 Future Opportunity

5. Global BCMA Targeting Drugs Market Opportunity by Region

5.1 US

5.2 Europe

5.3 Japan

5.4 Rest of World

6. Global BCMA Targeting Drugs Market by Cancer Type

6.1 Multiple Myeloma

6.2 Lymphoma

6.3 Leukemia

7. Blenrep (Belantamab Mafodotin-blmf) – First Approved BCMA Targeting Therapy

7.1 Overview

7.2 Dosage & Price Analysis

7.3 Sales Analysis

8. Abecma (Idecabtagene Vicleucel) – Second Approved BCMA Targeting Therapy

8.1 Overview

8.2 Dosage, Price & Sales Analysis

9. BCMA Targeting Drugs Sales Forecast 2026

9.1 Blenrep

9.2 Abecma

10. BCMA Targeting Drugs Clinical Trials Insight

10.1 By Phase

10.2 By Development Status

10.3 By Region

11. BCMA Targeting Drugs Market – Ongoing Research & Development

11.1 Ciltacabtagene Autoleucel (JNJ-68284528)

11.2 Allo715

11.3 CTX120

11.4 C-CAR088

11.5 CT053

11.6 HPN217

11.7 Pacanalotamab (AMG 420/ BI 836909)

11.8 PHE 885

11.9 bb21217

11.10 SEA BCMA

12. Global BCMA Targeted Drugs Clinical Trials Insight

12.1 Research

12.2 Preclinical

12.3 Clinical

12.4 Phase-0

12.5 Phase-I

12.6 Phase-I/II

12.7 Phase-II

12.8 Phase-II/III

12.9 Phase-III

12.10 Preregistration

13. Approved BCMA Targeted Drugs Clinical Insight

13.1 Belantamab Mafodotin – GlaxoSmithKline

13.2 Idecabtagene Vicleucel – Bluebird Bio/Celgene Corporation

14. Global BCMA Targeting Drug Market Dynamics

14.1 Market Drivers

14.2 Market Challenges

15. Global BCMA Targeting Drug Market Future Outlook

16. Competitive Landscape

16.1 Allogene Therapeutics

16.2 AbbVie

16.3 Amgen

16.4 BioTherapeutics

16.5 Bluebird Bio

16.6 Bristol Mayer Squibb

16.7 Carsgen Therapeutics

16.8 Celgene

16.9 Cogent Bioscience

16.10 CRISPR Therapeutics

16.11 GlaxoSmithKline

16.12 Harpoon Therapeutics

16.13 Hrain Biotechnology

16.14 iCell Gene Therapeutics

16.15 Johnson & Johnson

16.16 Juno Therapeutics

16.17 Novartis

16.18 Poseida Therapeutics

16.19 Seagen

16.20 Seattle Genetics

For more information about this report visit https://www.researchandmarkets.com/r/4570dw

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900